Phenotypic Drug Screening Services

Overview

Phenotypic drug screening is a whole-organism discovery technique that measures disease-relevant phenotypes in living zebrafish embryos or larvae to assess compound activity. In contrast to target-directed techniques, phenotypic screening allows the functional assessment of responses in a variety of biological systems, allowing identification of compounds with desirable therapeutic effects regardless of the molecular target.

Our Zebrafish Phenotypic Drug Screening Services employ disease models, high-content imaging, behavioral analysis and quantitative phenotyping to facilitate hit discovery, lead optimization, drug repositioning and mechanism exploration. This technology allows for thorough generation of in vivo data for candidate prioritization in early drug discovery by simultaneously tracking efficacy, developmental responses and early toxicity.

Why Use Zebrafish for Phenotypic Screening?

Phenotypic screening in zebrafish provides a unique combination of whole organism biology, scalable throughput and quantitative analysis and it is an ideal tool for early-stage drug discovery.

• Whole-Organism Responses

Evaluate compound effects on numerous organs and physiological systems in a single test that captures effectiveness, developmental alterations and systemic reactions in a real vertebrate.

• Multiparametric Readouts

Simultaneously quantify morphology, behavior, fluorescent reporter activity, organ function, survival, and other disease-related phenotypes to generate comprehensive biological profiles.

• Real-Time Imaging

Compound treatment can be applied to transparent embryos and larvae, enabling non-invasive visualization of dynamic biological processes with both brightfield and fluorescence imaging.

• Disease-Relevant Models

Provide phenotypic screening support employing genetic, chemically induced, xenograft, injury or transgenic zebrafish models that recapitulate disease-associated behaviors.

• Early Toxicity Detection

Monitor efficacy, developmental anomalies and organ-specific toxicity together to improve candidate selection and reduce late-stage attrition.

• Scalable Screening Format

Standardized multiwell plate formats and automated imaging workflows can be used to quickly screen large collections of compounds.

Phenotypic Readouts We Evaluate

Our platform supports quantitative analysis of diverse phenotypic endpoints, allowing comprehensive evaluation of compound responses at the whole-organism level.

Morphological Phenotypes

Morphological analysis provides a rapid assessment of developmental and structural changes following compound exposure. Quantifiable endpoints include:

• Body length
• Body axis curvature
• Craniofacial morphology
• Pericardial or yolk sac edema
• Pigmentation changes
• Developmental delay
• Organ morphology

Behavioral Phenotypes

Automated behavioral assays enable sensitive evaluation of neurological and pharmacological responses through quantitative movement analysis.

Typical endpoints include:

• Locomotor activity
• Swimming speed
• Distance traveled
• Light-dark response
• Seizure-like behavior
• Sleep/wake activity
• Startle response

Fluorescent Reporter Signals

Transgenic reporter models enable visualization and quantification of specific cell populations, signaling pathways, or disease processes.

Representative measurements include:

• Fluorescence intensity
• Fluorescent area
• Cell number
• Reporter activation or suppression
• Spatial signal distribution

Organ Function

Functional phenotyping enables assessment of compound effects on individual organs and physiological systems.

Common readouts include:

• Heart rate
• Blood flow
• Vascular development
• Liver morphology or fluorescence
• Neural activity-related phenotypes
• Kidney function and pronephric edema
• Eye and retinal phenotypes

Disease Progression

Disease-associated phenotypes can be quantitatively monitored to evaluate therapeutic efficacy across multiple disease models.

Representative endpoints include:

• Tumor burden
• Immune cell recruitment
• Neurodegeneration
• Muscle degeneration
• Lipid accumulation
• Infection burden

Survival and Development

General developmental health is evaluated throughout the study to distinguish pharmacological activity from nonspecific toxicity.

Typical measurements include:

• Survival rate
• Hatching rate
• Developmental stage
• Gross toxicity score

Available Disease Models for Phenotypic Screening

Our phenotypic drug screening platform supports a broad range of established and customizable zebrafish disease models to address diverse therapeutic areas and research objectives. Model selection is tailored to the biological question, target phenotype, and screening strategy, enabling robust evaluation of compound efficacy through disease-relevant phenotypic endpoints.

• Zebrafish Tumor Models
• Zebrafish Ocular Disease Models
• Zebrafish Cardiovascular Disease Models
• Zebrafish Neurological Disorder Models
• Zebrafish Infectious Disease Models
• Zebrafish Metabolic Disease Models
• Zebrafish Liver Disease Models
• Zebrafish Kidney Disease Models…

Assay Development and Phenotype Selection

Each phenotypic screening project is designed according to the biological question, disease model, and intended screening endpoint.

Our assay development process may include:

• Disease model selection or customization
• Definition of phenotypic endpoints
• Positive and negative control validation
• Optimization of treatment and observation windows
• Compound exposure strategy
• Imaging endpoint design
• Assay sensitivity evaluation
• Reproducibility assessment

Applications

Our zebrafish phenotypic screening platform supports a wide range of drug discovery and translational research programs, including:

• Phenotype rescue screening
• Disease model-based drug discovery
• In vivo efficacy screening
• Lead optimization
• Drug repurposing based on disease phenotypes
• Toxicity-informed candidate prioritization
• Mechanism exploration through phenotypic profiling